8-K: Runway Growth to Acquire SWK Holdings, Boosts Healthcare Focus

Runway Growth Finance Corp. announced a definitive merger agreement to acquire SWK Holdings Corporation, expanding its healthcare and life sciences portfolio.

Summary

• Runway Growth Finance Corp. (RWAY) has entered into a definitive merger agreement to acquire SWK Holdings Corporation (SWK).
• The acquisition is expected to be accretive to net investment income (NII) by mid-single digits during the first full quarter post-close.
• The transaction will increase Runway Growth's total assets to $1.3 billion on a pro forma basis.
• Healthcare investments within Runway Growth's portfolio are projected to increase from 14% to approximately 31% as of June 30, 2025, pro forma.
• The estimated purchase price is approximately $220 million, based on SWK's June 30, 2025 financials, including estimated SWK transaction expenses.
• Consideration includes a fixed stock component of $75.5 million in Runway Growth shares and approximately $145 million in cash.
• Runway Growth Capital LLC, the external investment adviser, will contribute an additional $9 million in cash for distribution to SWK stockholders.
• SWK's portfolio comprises 22 companies with an approximate fair value of $242 million as of August 15, 2025.
• The transaction is expected to close in late 2025 or the first quarter of 2026, subject to SWK shareholder and regulatory approvals.

Sentiment

Score: 8

Explanation: The filing announces a strategic acquisition with clear, quantifiable positive financial impacts such as NII accretion, increased assets, and improved portfolio diversification. Management commentary is highly optimistic about long-term value creation and growth strategies.

Positives

• Meaningfully advances strategy to diversify and optimize the portfolio by adding high-quality healthcare and life sciences investments.
• Enhances earnings power, more than offsetting anticipated loan repayments, with expected mid-single-digit NII accretion.
• Reinforces portfolio strength and is expected to generate long-term value for shareholders through disciplined growth.
• Increases total assets to $1.3 billion pro forma, driving portfolio scale and diversification.
• Expands investment capabilities and deal sourcing teams with the addition of SWK's healthcare and life sciences teams.
• Enhances already strong portfolio metrics through high-quality investments and a meaningful reduction in average loan size.
• Offers a repeatable blueprint for future non-dilutive deals in the venture and growth investment ecosystem.
• Bolstered by the support of the BC Partners Credit platform for organic and inorganic growth strategies.
• Expected to drive improvements in dividend coverage and Return on Equity (ROE).
• Expands Runway Growth's pro-forma leverage ratio and increases nominal leverage capacity, supporting continued risk-adjusted returns.
• Broadens the shareholder base and improves trading liquidity of common shares through the issuance of $75.5 million in Runway Growth shares to SWK shareholders.

Risks

• Uncertainty regarding the ability of the parties to consummate the merger on the expected timeline, or at all.
• Risks associated with realizing the expected synergies, savings, and anticipated benefits of the merger, including expense and cost elimination.
• Potential impact of the merger on the depth of trading in Runway Growth's shares of common stock post-closing.
• Possibility that any or all conditions to the consummation of the merger may not be satisfied or waived.
• Risks related to diverting management's attention from ongoing business operations.
• Potential termination of the merger agreement.
• Uncertainty regarding the future operating results and net investment income projections of the combined company.
• Ability of Runway Growth Capital LLC to implement its future plans with respect to the combined company.
• Ability of Runway Growth Capital LLC and its affiliates to attract and retain highly talented professionals.
• Business prospects of the combined company and the prospects of its portfolio companies.
• Expected financings and investments and additional leverage that the combined company may seek to incur in the future.
• Adequacy of the cash resources and working capital of the combined company.
• Risk that stockholder litigation in connection with the merger may result in significant costs of defense and liability.
• Risks associated with development programs for medical products, including the high degree of risk and low commercialization rate in research and development.

Future Outlook

The acquisition is expected to generate mid-single-digit run-rate NII accretion, improve dividend coverage and ROE, and expand the pro-forma leverage ratio. Runway Growth plans to pursue continued growth through both organic and inorganic strategies, supported by the BC Partners Credit platform, aiming to increase nominal leverage capacity and support risk-adjusted returns.

Management Comments

• David Spreng, Founder and CEO of Runway Growth, stated: "This transaction meaningfully advances our strategy to diversify and optimize our portfolio by adding SWK's high-quality investments in the key sectors of healthcare and life sciences."
• Spreng also noted: "At the same time, we are enhancing our earnings power, more than offsetting the anticipated loan repayments we previously signaled, and we expect to deliver mid-single-digit NII accretion."
• Spreng emphasized: "This transaction reinforces the strength of Runway Growth's portfolio as we work to generate long-term value for our shareholders through disciplined growth and venture debt investing with a focus on excellent credit quality in the sectors we know best."
• Spreng added: "Looking ahead, and with the full support of BC Partners Advisors L.P., we are pursuing growth through both organic and inorganic strategies as a permanent capital vehicle backed by the $10 billion BC Partners Credit platform."
• Spreng concluded: "We are doing all of this while growing our shareholder base, improving our existing robust portfolio metrics and increasing our total assets to $1.3 billion pro forma with the SWK merger transaction."

Industry Context

This acquisition positions Runway Growth to significantly expand its presence in the high-growth healthcare and life sciences sectors, aligning with broader industry trends of increasing investment in these areas. By acquiring SWK, a specialty finance company focused on these sectors, Runway Growth is enhancing its expertise and market share, potentially creating a more diversified and resilient portfolio compared to peers heavily concentrated in other venture debt segments.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry benchmark comparison. The focus is on the internal benefits and strategic alignment of the merger for Runway Growth Finance Corp.

Corporate Governance

Legal Proceedings

• Stockholder litigation in connection with the merger is identified as a potential risk that may result in significant costs of defense and liability.

Related Party Transactions

• Runway Growth Capital LLC, in its capacity as Runway Growth's external investment adviser and an affiliate of BC Partners Advisors L.P., will contribute $9 million in cash for distribution as consideration to the stockholders of SWK.

Stakeholder Impact

• Shareholders of Runway Growth: Expected to benefit from NII accretion, improved dividend coverage, enhanced ROE, increased scale, and long-term value creation.
• Shareholders of SWK: Will receive a combination of Runway Growth shares and cash as consideration for their holdings.
• Employees: Members of SWK's healthcare and life sciences teams will be added to Runway Growth Capital's investment and deal sourcing teams, indicating potential integration and expansion.
• Customers (lateand growth-stage companies): Runway Growth will expand its position and investment capabilities in the healthcare and life sciences sector, potentially offering more diverse and specialized financing solutions.

Next Steps

• SWK shareholder approval of the merger.
• Regulatory approvals for the transaction.
• Satisfaction of other customary closing conditions.
• Filing of a Combined Proxy Statement and Prospectus with the SEC.
• Conference call to discuss the transaction on October 10, 2025.
• Expected closing of the transaction in late 2025 or the first quarter of 2026.

Key Dates

Recommendation

The acquisition of SWK Holdings is a highly strategic move for Runway Growth, significantly diversifying its portfolio into the high-growth healthcare and life sciences sectors. The expected mid-single-digit NII accretion, coupled with improvements in dividend coverage, ROE, and overall financial profile, presents a compelling investment case. The increased scale to $1.3 billion in assets and the support from BC Partners Credit platform further strengthen the company's position for future organic and inorganic growth. While merger-related risks exist, the clear financial and strategic benefits outweigh these, suggesting a positive outlook for the stock.

Keywords

Merger, Acquisition, Healthcare, Life Sciences, Specialty Finance, Venture Debt, BDC, NII Accretion, Portfolio Diversification, SWK Holdings, Runway Growth Finance